NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD
  • XY Feed
  • 24-HOUR Pass ↗
  • Push Notifications
Sign in Subscribe

Affle Agrees to Buy Israeli Ad-Tech Firm Perion for $420 Million

Shareholders will receive $11.70 per share, a 34.5% premium to the recent close.

Affle Agrees to Buy Israeli Ad-Tech Firm Perion for $420 Million
perion.com/
Already have an account? Sign in.
11/02/2026 · 8:01 AM
PERI
/ Read more

Feed↓

UBS Upgrades Rivian to Buy, Calls 19% Sell-Off a Buying Opportunity Ahead of R2 Ramp
11/02/2026 · 2:36 PM

UBS Upgrades Rivian to Buy, Calls 19% Sell-Off a Buying Opportunity Ahead of R2 Ramp

UBS upgrades Rivian to Buy from Neutral with a $17 price target, citing valuation and a buying opportunity ahead of the R2 production ramp.

/ Subscriber only
Anthropic’s Revenue Hits $17 Billion in Q3 as Amended IPO Filing Reveals Massive Infrastructure Commitments
11/02/2026 · 11:51 AM

Anthropic’s Revenue Hits $17 Billion in Q3 as Amended IPO Filing Reveals Massive Infrastructure Commitments

Anthropic reported roughly $17B in Q3 revenue and $33.24B for the first nine months in its amended IPO filing, alongside $895B in compute commitments.

/ Subscriber only
RBC Capital Sees Mixed Q3 for Krystal Biotech as Vyjuvek Beats but Pipeline Readouts Slip
11/02/2026 · 10:05 AM

RBC Capital Sees Mixed Q3 for Krystal Biotech as Vyjuvek Beats but Pipeline Readouts Slip

RBC calls Krystal’s Q3 mixed. Vyjuvek beat expectations, but key pipeline readouts for DEB and CF now slip into 2027. Outperform, $400 PT.

/ Subscriber only
Explore
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD
  • XY Feed
  • 24-HOUR Pass ↗
  • Push Notifications
More
  • Sign up
  • Sign in
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Terms/Privacy
  • UP↑
Get alerts

Be the first to know when deals break, stocks move, or biotech headlines hit.

Email address Subscribe
DON'T FALL BEHIND. ©2026
For informational purposes only. Not financial advice.
NOTRELOAD AI